MicroRNA-138 regulation promotes the efficacy of oncolytic herpes virus G47Δ for malignant brain tumor therapy [0.03%]
microRNA-138调节可促进溶瘤 herpes病毒G47Δ治疗恶性脑肿瘤的疗效
Seisaku Kanayama,Takeshi Haraguchi,Hideo Iba et al.
Seisaku Kanayama et al.
G47Δ, a third-generation oncolytic herpes simplex virus type 1, is a promising therapeutic agent for malignant glioma. We investigated whether inhibition of host microRNA-138 (miR-138), a regulator of the viral immediate-early protein ICP0...
Repurposing the SSRI paroxetine increases lymphocyte mobilization and improves the efficacy of measles virus-based immunovirotherapy [0.03%]
氟西汀再利用可增加淋巴细胞动员并提高基于麻疹病毒的免疫病毒疗法的功效
Georgios M Stergiopoulos,Susanna C Concilio,Kim B Viker et al.
Georgios M Stergiopoulos et al.
Glioblastoma (GBM) is the most common primary malignant brain tumor, with a poor prognosis and limited response to immunotherapy. Systemic immunosuppression in GBM is a significant challenge partly driven by T cell sequestration in the bone...
Safety and feasibility of talimogene laherparepvec in peritoneal surface malignancies: Results from the TEMPO trial [0.03%]
瘤囊肿瘤局部应用溶瘤病毒T-VEC的安全性和可行性——TEMPO试验结果
John H Stewart th,Donna Niedzwiecki,Melissa Lowe et al.
John H Stewart th et al.
Peritoneal surface malignancies (PSMs) remain a therapeutic challenge, particularly in patients with unresectable disease who cannot benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. The Talimogene Laherparep...
Non-viral TcBuster transposon engineering of CD70-CAR natural killer cells for the treatment of osteosarcoma [0.03%]
用于治疗骨肉瘤的CD70-CAR自然杀伤细胞的非病毒TcBuster转座子工程化技术
Gabrielle M Robbins,Jae-Woong Chang,Joshua B Krueger et al.
Gabrielle M Robbins et al.
Osteosarcoma (OSA) is the most common primary bone tumor in children and adolescents, yet outcomes have remained largely unchanged for over 40 years. While chimeric antigen receptor (CAR) T cell therapy has shown success in blood cancers, i...
Dean A Lee
Dean A Lee
Novel syngeneic model of anti-mouse CLDN18.2 CAR -T therapy for gastric cancer demonstrates a synergy with TGF-β and PD-L1 inhibitors [0.03%]
新型抗小鼠CLDN18.2嵌合抗原受体CAR-T细胞治疗胃癌模型展现出与转化生长因子-β和PD-L1抑制剂的协同作用
Min-Jung Seo,Jin Hue Jeong,Han Na Park et al.
Min-Jung Seo et al.
There are very few syngeneic mouse cell line models available for gastric cancer owing to the rarity of stomach epithelium-specific promoter. Mouse cell line models are useful to study an immunologically intact tumor microenvironment, espec...
A monoclonal antibody W1 blocks mesothelin-mediated tumor progression [0.03%]
抗_mesothelin_单克隆抗体_W1_可阻断由_mesothelin_介导的肿瘤进展
Qingguang Wang,Guangcan Cao,Mingxin Li et al.
Qingguang Wang et al.
Mesothelin (MSLN) represents an attractive and potential biomarker for targeted cancer therapy. Although MSLN has been implicated in mediating tumorigenesis, its precise physiological function remains incompletely elucidated. Moreover, only...
Mesenchymal stem cell-derived extracellular vesicle therapy in breast cancer: A systematic review and meta-analysis of in vitro studies [0.03%]
乳腺癌中骨髓间充质干细胞源性外泌体治疗的体内研究系统综述和meta分析
Nadiar M Mussin,Kulyash R Zhilisbayeva,Akmaral Baspakova et al.
Nadiar M Mussin et al.
Mesenchymal stem/stromal cell-derived extracellular vesicles (MSC-EVs) have emerged as promising cell-free therapeutics for breast cancer due to their innate tumor tropism and molecular delivery capacity. This systematic review and meta-ana...
CAR-T cell exhaustion in B cell lymphoma: Current status, mechanisms, and potential solutions [0.03%]
B细胞淋巴瘤的CAR-T细胞耗竭：现状、机制与潜在解决方案
Ruocong Zhao,Jianglong Xia,Yuanyuan Zheng et al.
Ruocong Zhao et al.
Chimeric antigen receptor T cell (CAR-T) therapy represents a revolutionary approach in the treatment of refractory or relapsed hematological malignancies including lymphoma. Despite its efficacy, a significant subset of patients experience...
Evaluation of dasatinib and ponatinib for the control of CD123 CAR-T cell functionalities [0.03%]
达沙替尼和 ponatinib对CD123CAR-T细胞功能的调控作用评估
Charles-Frédéric Mantion,Sabeha Biichlé,Xavier Roussel et al.
Charles-Frédéric Mantion et al.
CD123 CAR-T cells (CAR123) represent a promising therapeutic approach for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and CD123+ acute myeloid leukemia (AML). However, the pro-inflammatory environment resulting from CAR-T cell acti...